NEWS –  A new IVF technique combining DNA from three individuals has successfully prevented inherited diseases in eight children in the UK, offering hope to families worldwide

HIGHLIGHTS

• In 2017, the UK legalized three-parent IVF, sparking debates about its potential acceptance in the United States.

• The technique is intended for women with mitochondrial diseases who want to avoid passing on genetic disorders to their children.
• It involves combining the nuclear DNA of the intended mother with the healthy mitochondrial DNA of an egg donor, resulting in a child with DNA from three individuals.
• Importantly, the donor DNA only makes up 0.2% of the child’s genome, preserving the biological link to the mother.
• Conditions targeted by this procedure include Leigh’s disease, Wolff-Parkinson-White syndrome, and Leber’s hereditary optic neuropathy (LHON).
• Although medically promising, the technique faces ethical and regulatory hurdles in the U.S.
• Critics argue that it could lead to “designer babies” and misuse of genetic manipulation technologies.
• The FDA has yet to approve the procedure, delaying its clinical application despite rising interest among U.S. fertility experts.
• Currently, patients in the U.S. can opt for Preimplantation Genetic Diagnosis (PGD) to screen embryos for genetic disorders like Huntington’s disease, cystic fibrosis, and cancers.
• The future of three-parent IVF in the U.S. depends on regulatory clarity and ethical consensus.